Safety and Efficacy of CD10367 in Psoriasis Vulgaris

Summary

This was an exploratory, single-center, investigator blinded, randomized, controlled, intra-individual study, involving participants with psoriasis vulgaris. The objective was to evaluate, in a modified Dumas-Scholtz psoriasis mini-zone test, the safety and efficacy of CD10367 solution at 1% and 3% after a 3-week treatment period of once daily application.

Timeline

Start

2016-11-03

Primary completion

2017-03-24

Completion

2017-03-24

Drugs

Indications